Aurora Cannabis (ACB) vs BioAge Labs (BIOA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioAge Labs (BIOA) has outperformed Aurora Cannabis (ACB) over the past year, gaining 11.8% versus a loss of 27.7%. BioAge Labs is the larger company by market cap ($286.4 million vs $279.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACB | BIOA |
|---|---|---|
| Share price | $4.42 | $6.24 |
| Market cap | $279.83M | $286.40M |
| 1-day change | -0.90% | -0.32% |
| YTD return | +5.69% | -52.68% |
| 1-year return | -27.71% | +11.79% |
| 5-year return | -93.66% | — |
| EPS (TTM) | $-0.61 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.67 | $25.96 |
| 52-week low | $2.56 | $5.04 |
| Distance from 52-week high | -33.68% | -75.96% |
| Analyst consensus | buy | none |
| Avg. price target upside | — | +470.99% |
| Average volume | 1.36M | 913.77K |
| Shares outstanding | 63.31M | 45.90M |
| Employees | 1,028 | 60 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIOA has outperformed ACB by 39.5 percentage points over the past year.
About Aurora Cannabis
ACB stock →Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products.
Health Care · Medicinal Chemicals and Botanical Products · 1,028 employees
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
ACB vs BIOA FAQ
Which is bigger, Aurora Cannabis or BioAge Labs?
BioAge Labs (BIOA) is larger, with a market capitalization of $286.40M compared with $279.83M for Aurora Cannabis (ACB).
Which stock has performed better over the past year, ACB or BIOA?
BIOA returned +11.79% over the past 12 months, compared with -27.71% for ACB (price return, excluding dividends). Past performance does not predict future results.
Are Aurora Cannabis and BioAge Labs in the same industry?
Both are in the Health Care sector, but in different industries: Medicinal Chemicals and Botanical Products for Aurora Cannabis and Biotechnology: Pharmaceutical Preparations for BioAge Labs.